+32 (0)472 88 76 22
iTeos Therapeutics is a publicly-held (NASDAQ: ITOS), clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies.
Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (UCLouvain) in 2011.
In March 2020, the Company completed a $125 million Series B2 financing, and in July 2020, they completed their IPO raising over $230million of gross proceeds. In June 2021, iTeos entered into a transformative $2.145 billion co-development and co-commercialization agreement with GSK for EOS-448, iTeos’s anti-TIGITmonoclonal antibody. As a well-capitalized biotech company iTeos is positioned to continue to develop its clinical pipeline and maintain their investments in its discovery research team to leverage its fantastic science to improve the lives of cancer patients.
For more information, please visit www.iteostherapeutics.com.
iTeos Therapeutics is now a world-class biotech in cancer immunotherapy. To carry on its growth, expand its pipeline and reinforce its team in Gosselies, iTeos Therapeutics is looking for a Research Assistant – Target Discovery & Validation.
Within the Target Discovery & Validation group (R&D Department), iTeos Therapeutics is looking for a highly motivated and skilled Research Assistant who will perform laboratory work to support the selection and validation of innovative targets with the goal to develop breakthrough cancer immunotherapies.
Your main responsibilities are:
Your application and related information will remain strictly confidential.